Eisai and Biogen Inc announced that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD(TM)) March 15-20 in Barcelona, Spain and virtually.
The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking...
CE Marking (Conformite Europeene) in the European Union has been granted to Abbott Labs to market its rapid, high-throughput PLEX-ID(TM)...
Objectives: To examine the prevalence of self-reported symptoms of obstructive sleep apnoea (OSA) in relation to asthma, respiratory symptoms and pulmonary function.